Intervention Review

You have free access to this content

Fluoroquinolones for treating tuberculosis

  1. Lilia E Ziganshina1,*,
  2. Stephen B Squire2

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 13 OCT 2007

DOI: 10.1002/14651858.CD004795.pub3

Database Title

Additional Information

How to Cite

Ziganshina LE, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD004795. DOI: 10.1002/14651858.CD004795.pub3.

Author Information

  1. 1

    Kazan State Medical Academy, Department of Clinical Pharmacology and Pharmacotherapy, Kazan, Tatarstan, Russian Federation

  2. 2

    Liverpool School of Tropical Medicine, Clinical Group, Liverpool, Merseyside, UK

*Lilia E Ziganshina, Department of Clinical Pharmacology and Pharmacotherapy, Kazan State Medical Academy, 11 Mushtari Street, 420012, 14-15 Malaya Krasnaya Street, 420015, Kazan, Tatarstan, Russian Federation. lezign@mail.ru. lezign@gmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Summary (58K)Standard (408K)Full (585K)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
Burman 2006 {published data only}
  • Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. American Journal of Respiratory & Critical Care Medicine 2006;174(3):331-8.
El-Sadr 1998 {published data only}
  • El-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, et al. Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clinical Infectious Diseases 1998;26(5):1148-58.
Huang 2000 {published data only}
  • Huang CS, Wu CC. Observation of the clinical efficacy of sparfloxacin in the treatment of multiple drug resistance pneumonial tuberculosis. Chinese Journal of Antibiotics 2000;25(4):302-3.
Ji 2001 {published data only}
  • Ji YM, Dong LH, Wang Q, Yu WQ. Short-term observating of curative effects in treatment of multiple-drug resistance pulmonary tuberculosis with sparfloxacin and ofloxacin. Journal of Postgraduates of Medicines 2001;24(7):32-3.
Kennedy 1993 {published data only}
  • Kennedy N, Fox R, Uiso L, Ngowi FI, Gillespie SH. Safety profile of ciprofloxacin during long-term therapy for pulmonary tuberculosis. Journal of Antimicrobial Chemotherapy 1993;32(6):897-902.
Kennedy 1996 {published data only}
  • Kennedy N, Berger L, Curram J, Fox R, Gutmann J, Kisyombe GM, et al. Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis. Clinical Infectious Diseases 1996;22(5):827-33.
  • Kennedy N, Fox R, Kisyombe GM, Saruni AO, Uiso LO, Ramsay AR, et al. Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis. American Review of Respiratory Disease 1993;148(6 Pt 1):1547-51.
Kohno 1992 {published data only}
Lu 2000 {published data only}
  • Lu Y, Zhu L, Duan L. Antituberculosis effect of levofloxacin. Zhonghua Jiehe He Huxi Zazhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 2000;23(1):50-4.
Mohanty 1993 {published data only}
Saigal 2001 {published data only}
  • Saigal S, Agarwal SR, Nandeesh HP, Sarin SK. Safety of an ofloxacin-based antitubercular regimen for the treatment of tuberculosis in patients with underlying chronic liver disease: a preliminary report. Journal of Gastroenterology and Hepatology 2001;16(9):1028-32.
    Direct Link:
Sun 2000 {published data only}
  • Sun W, Wenyi C, Cunzhi L, Yanhong Y, Yuzhen X, Zhaosheng S. A randomized controlled study of sparfloxacin and ofloxacin in the treatment of multiple drug resistant pulmonary tuberculosis. Chinese Journal of Antibiotics 2000;25(1):52-4.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
Andries 2005 {published data only}
Anonymous 1997 {published data only}
  • Anonymous. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council. Tubercle and Lung Disease 1997;73(1):59-67.
Chambers 1998 {published data only}
Chen 2003 {published data only}
  • Chen QL, Chen L, Yin JJ. A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis. Zhonghua Jiehe He Huxi Zazhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 2003;26(8):454-7.
Chukanov 2006 {published data only}
  • Chukanov VI, Komissarova OG, Maishin VI, Abdullaev RI, Kononets AS. Efficiency of a new standard chemotherapy regimen in the treatment of patients with recurrent pulmonary tuberculosis. Problemy Tuberculeza I Boleznej Legkih 2006, (8):9-13.
Estebanez 1992 {published data only}
  • Estebanez Zarranz MJ, Martinez-Sagarra JM, Alberte A, Amon Sesmero J, Rodriguez Toves A. Treatment of urogenital tuberculosis with ofloxacin. Preliminary study. Actas Urologicas Espanolas 1992;16(1):64-8.
Gosling 2003 {published data only}
  • Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, et al. The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 2003;168(11):1342-5.
Grishin 1998 {published data only}
  • Grishin VK, Polunina TE. Lomefloxacin in phthisiatric practice. Antibiotiki i Khimioterapiia 1998;43(10):17-8.
Johnson 2006 {published data only}
  • Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. International Journal of Tuberculosis & Lung Disease 2006;10(6):605-12.
Kawahara 1992 {published data only}
  • Kawahara S, Eirei J. Evaluation of new antitubercular agents--new quinolone agents. Kekkaku 1992;67(10):679-82.
Kumar 2004 {published data only}
  • Kumar AK, Gurumurthy P. Disposition of uric acid upon administration of ofloxacin alone and in combination with other anti-tuberculosis drugs. Indian Journal of Experimental Biology 2004;42(3):323-5.
Marra 2005 {published data only}
O'Brien 1994 {published data only}
Pletz 2004 {published data only}
  • Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrobial Agents and Chemotherapy 2004;48(3):780-2.
Sirgel 1997 {published data only}
  • Sirgel FA, Botha FJ, Parkin DP, Van de Wal BW, Schall R, Donald PR, et al. The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine 1997;156(3 Pt 1):901-5.
Sirgel 2000 {published data only}
  • Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, et al. A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. Journal of Antimicrobial Chemotherapy 2000;45(6):859-70.
Sokolova 1998 {published data only}
  • Sokolova GB, Kunichan AD, Koriakin VA, Lazareva IaV. Lomefloxacin in complex treatment of acute progressive form of pulmonary tuberculosis. Antibiotiki i Khimioterapiia 1998;43(10):10-2.
Suo 1996 {published data only}
TRC 2002 {published data only}
  • Tuberculosis Research Centre (Indian Council of Medical Research), Chennei. Shortening short course chemotherapy: a randomized clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian Journal of Tuberculosis 2002;49(1):27-38.
Valerio 2003 {published data only}
  • Valerio G, Bracciale P, Manisco V, Quitadamo M, Legari G, Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. Journal of Chemotherapy 2003;15(1):66-70.
Venter 2006 {published data only}
  • Venter WDF, Panz VR, Feldman Ch, Joffe BI. Adrenocortical function in hospitalised patients with active pulmonary tuberculosis receiving a rifampicin-based regimen - a pilot study. South African Medical Journal 2006;96(1):62-6.
Wang 2006 {published data only}
  • Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006;61(10):903-8.
Yoon 2005 {published data only}
  • Yoon YS, Lee HI, Yoon HI, Yoo CG, Kim YW, Han SK, et al. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia. International Journal of Tuberculosis & Lung Disease 2005;9(11):1215-9.
Zhang 1997 {published data only}
  • Zhang Y, Qian H, Chen M. Bronchofiberscope and catheter intervention in treatment of multi-drug resistant pulmonary tuberculosis. Zhonghua Jiehe He Huxi Zazhi [Chinese Journal of Tuberculosis and Respiratory Diseases] 1997;20(6):354-7.
Zhang 2006 {published data only}
  • Zhang X, Li M, Hu CM, Yu J, Lin FS, Mao KJ, et al. Clinic assessment of rifabutin in the treatment of multidrug-resistant pulmonary tuberculosis. Chinese Journal of Antibiotics 2006;31(4):223-4+242.
Zhao 2003 {published data only}
  • Zhao RZ, Wang QM, Zhang PC, Zhang HM. Therapeutic effects of levofloxacin-containing regimen in patients with retreated pulmonary tuberculosis. Chinese Journal of Antibiotics 2003;28(8):497-9.
Zheng 2004 {published data only}
  • Zheng XM, Li SM, Xing BC. Short-term effect of treatment protocol utilizing levofloxacin, pasiniazide and M.Vaccae on multi-drug resistant pulmonary tuberculosis. Di Yi Jun Yi Da Xue Xue Bao [Academic Journal of the First Medical College of PLA] 2004;24(5):574-5.
Zhu 2006 {published data only}
  • Zhu LZ, Fu Y, Chu NH, Ye ZZ, Xiao HP, Wang W, et al. A controlled clinical trial of long course chemotherapy regimens containing rifabutin in the treatment of multi-drug resistant pulmonary tuberculosis. Chinese Journal of Tuberculosis & Respiratory Diseases 2006;29(8):520-3.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
Abdullah 1997 {published data only}
  • Abdullah A, Abu-Hussein AH, Al-Akshar M, Abdel R, Ads CH, El Taieb S. Ofloxacin in the treatment of primary drug resistant pulmonary tuberculosis (PDR-TB). European Respiratory Journal 1997;10 Suppl:25214.
Abdullah 1998 {published data only}
  • Abdullah A, Hussein A, Al-Akshar M, Ads CH, El-Taieb S. Ofloxacin dosage in the treatment of multidrug resistant pulmonary tuberculosis (MDR-TB). European Respiratory Journal 1998;12 Suppl:28367.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
ISRCTN07062956 {published data only}
  • ISRCTN 07062956. A randomised comparison of ciprofloxacin, levofloxacin and gatifloxacin for the treatment of adults with tuberculous meningitis. www.controlled-trials.com/ISRCTN07062956/07062956 (accessed 27 July 2007).
ISRCTN13670619 {published data only}
  • ISRCTN13670619. A comparative study of the bactericidal and sterilizing activity of three fluoroquinolones: gatifloxacin, moxifloxacin and ofloxacin substituted for ethambutol in the 2 month initial phase of the standard anti-tuberculosis treatment regimen also containing rifampicin, isoniazid and pyrazinamide (South Africa). www.controlled-trials.com/ISRCTN13670619/ISRCTN13670619 (accessed 27 July 2007).
ISRCTN44153044 {published data only}
  • ISRCTN44153044. An international multicentre controlled clinical trial to evaluate high dose RIFApentine and a QUINolone in the treatment of pulmonary tuberculosis. www.controlled-trials.com/ISRCTN44153044/ISRCTN44153044 (accessed 27 July 2007).
ISRCTN85595810 {published data only}
  • ISRCTN85595810. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis. www.controlled-trials.com/mrct/trial/260713/REMoxTB (accessed 27 July 2007).
NCT00144417 {published data only}
  • NCT00144417. Evaluation of a moxifloxacin-based, isoniazid-sparing regimen for tuberculosis treatment. www.clinicaltrials.gov/show/NCT00144417 (accessed 23 July 2007).
NCT00216385 {published data only}
  • NCT00216385. A controlled trial of a 4-month quinolone-containing regimen for the treatment of pulmonary tuberculosis. clinicaltrials-nccs.nlm.nih.gov/ct2/show/NCT00216385 (accessed 23 July 2007).
NCT00396084 {published data only}
  • NCT00396084. Randomized, open label, multiple dose Phase I study of the early bactericidal activity of linezolid, gatifloxacin, levofloxacin, and moxifloxacin in HIV-non-infected adults with Initial episodes of sputum smear-positive pulmonary tuberculosis (DMID 01-553). clinicaltrials.gov/ct/show/NCT00396084?order=11 (accessed 27 July 2007).

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
Alangaden 1997
Anon 1983
  • Anonymous. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis. Tubercle 1983;64(3):153-66.
Blumberg 2003
  • Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. American Journal of Respiratory Critical Care Medicine 2003;167(4):603-62.
Burman 1999
  • Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clinical Infectious Diseases 1999;28(3):419-30.
Chan 2004
  • Chan ED, Laurel V, Strand MJ, Chan JF, Huynh M-LN, Goble M, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine 2004;169(10):1103-9.
Corbett 2003
  • Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Archives of Internal Medicine 2003;163(9):1009-21.
Daley 1992
  • Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR Jr, et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. New England Journal of Medicine 1992;326(4):231-5.
El-Sadr 2001
  • El-Sadr WM, Perlman DC, Denning E, Marts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clinical Infectious Diseases 2001;32(4):623-32.
Gillespie 1998
Ginsburg 2003
Grzybowski 1975
  • Grzybowski S, Barnett GD, Styblo K. Contacts of cases of active pulmonary tuberculosis. Bulletin of the International Union Against Tuberculosis 1975; Vol. 50, issue 1:90-106.
Higgins 2006
  • Higgins JPT, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 1 July 2007).
Jacobs 1999
Jüni 2001
Kochi 1991
Loddenkemper 2002
Martindale 1996
  • Reynolds JEF, Parfitt K, Parsons AV, Sweetmann SC, editors. Martindale: the extra pharmacopoeia. 1st Edition. London: Royal Pharmaceutical Society, 1996:1881.
Pablos-Mendez 2002
  • Pablos-Mendez A, Gowda DK, Frieden TR. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bulletin of the World Health Organization 2002; Vol. 80, issue 6:489-95.
Portaels 1999
  • Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. International Journal of Tuberculosis and Lung Disease 1999;3(7):582-8.
Reichman 1996
Review Manager 5
  • The Nordic Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.0. Copenhagen: The Nordic Centre, The Cochrane Collaboration, 2008.
Shafer 1995
STS/BMRC 1981
  • Anon. Clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercule 1981;62(2):95-102.
Telzak 1999
  • Telzak EE, Chirgwin KD, Nelson ET, Matts JP, Sepkowitz KA, Benson CA, et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. International Journal of Tuberculosis and Lung Disease 1999;3(4):337-43.
Wei 2000
  • Wei S, Wenyi C, Cunzhi L, Yanhong Y, Yuzhen X, Zhaosheng S. A randomized controlled study of sparfloxacin and ofloxacin in the treatment of multiple drug resistant pulmonary tuberculosis. Chinese Journal of Antibiotics 2000;25(1):53-5.
WHO 2003
  • WHO Global Tuberculosis Programme. Treatment of tuberculosis: guidelines for national programmes [WHO/CDS/TB/2003.313]. 3rd Edition. Geneva: World Health Organization, 2003:13.
WHO 2006
  • World Health Organization. Stop TB Dept. Guidelines for the programmatic management of drug-resistant tuberculosis [WHO/HTM/TB/2006.361]. Geneva: World Health Organization, 2006:38-53.
WHO 2007a
  • World Health Organization. Stop TB Dept. Global tuberculosis control : surveillance, planning, financing : WHO report 2007 [WHO/HTM/TB/2007.376]. http://www.who.int/tb/publications/global_report/2007/download_centre/en/index.html. Geneva: World Health Organization, 2007 (accessed August 2007).
WHO 2007b
  • World Health Organization. Fact Sheet No 104: Tuberculosis. www.who.int/mediacentre/factsheets/fs104/en/index.html March 2007 (accessed 1 August 2007).
WHO 2007c
  • World Health Organization. WHO model list of essential medicines: 15th edition, revised March 2007. WHO Drug Information 2007;21(2):95-111.
Woldehanna 2004
  • Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews 2004, Issue 1. [DOI: ]
Yew 2000
  • Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, et al. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens. Chest 2000;117(3):744-51.
Yew 2001
Yew 2003
  • Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003;124(4):1476-81.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
  6. References to other published versions of this review
Ziganshina 2005
  • Ziganshina LE, Vizel AA, Squire SB. Fluoroquinolones for treating tuberculosis. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: ]
View Full Article (HTML) Summary (58K)Standard (408K)Full (585K)